- Company
- K-Bios seek drugs to be used in combination with ADCs
- by Son, Hyung Min Dec 26, 2024 05:50am
- The domestic pharmaceutical and bio-industry are changing clinical trial protocols and confirming the possibility of their use in combination therapy with antibody-drug conjugates (ADCs). In particular, a growing number of companies are trying to use their drugs in combination with Enterhu, which has shown an effect across solid cancers For e
- Company
- Losartan prescription market has grown 15% in 3 years
- by Chon, Seung-Hyun Dec 26, 2024 05:50am
- The prescription market for the antihypertensive drug losartan has shown an upward trend. Its market plummeted in 2021 following the detection of excess impurities in all losartan products but has since recovered obviously. Prescriptions of both single and combination losartan drugs have risen over 10% from three years ago. Analysts say the recu
- Company
- Soyun Oh appointed to head Organon Malaysia
- by Whang, byung-woo Dec 24, 2024 06:22am
- Organon Korea announced today that Soyun Oh, who currently heads the company’s Sales and Customer Department, has been appointed Country Lead for Organon Malaysia, effective January 1, 2025. With more than 26 years of experience in the industry, Oh has been with Organon since its inception in Korea and has successfully led the company'
- Company
- SK Bioscience and Sanofi reinforce vaccine R&D partnership
- by Dec 24, 2024 06:22am
- SK Bioscience has expanded the scope of its vaccine development partnership with global pharmaceutical giant Sanofi. The goal is to develop a next-generation vaccine that is more advanced than the existing jointly developed pneumococcal protein-conjugate vaccine. The expanded agreement is more than 10 times larger in total value than the
- Company
- Keytruda faces challenge from 'Steep Slope' CDRC
- by Moon, sung-ho Dec 24, 2024 06:21am
- The Cancer Disease Review Committee (CDRC) of the Health Insurance Review and Assessment Service (HIRA) is the first and most challenging hurdle in reviewing the insurance reimbursement of new anticancer drugs. A required step toward obtaining reimbursement listing, the committee has been nicknamed a "steep slope," giving many anticancer drug
- Company
- Oral contraceptive market expands
- by Whang, byung-woo Dec 23, 2024 04:19pm
- As the oral contraceptive market expands, Yaz seems to maintain its market share despite the introduction of generics. According to a report by global market research firm Research and Markets, the global oral contraceptive market is expected to grow from approximately KRW 33.8 trillion (USD 23.6 billion) in 2023 to around KRW 67.3 trillion (
- Company
- Multidisciplinary approach required for urothelial carcinoma
- by Whang, byung-woo Dec 23, 2024 05:50am
- New drugs, such as immunotherapy, have been introduced as the first-line treatment for urothelial carcinoma, which was primarily treated with platinum-based chemotherapies. The treatment landscape for the disease is constantly evolving. As more treatment options became available, doctors are now discussing the optimal treatment for each disea
- Company
- Takeda's Firazyr reimbursable up to four doses per Rx
- by Whang, byung-woo Dec 23, 2024 05:49am
- Takeda Pharmaceuticals Korea announced on December 19 that the National Health Insurance reimbursement coverage for Firazyr (ingredient: icatibant acetate), a treatment for acute attacks of hereditary angioedema (HAE), has been expanded to up to four doses per prescription starting this December. According to partial revisions to the 'Cov
- Company
- LG Chem wins Zemiglo patent dispute
- by Kim, Jin-Gu Dec 20, 2024 05:46am
- LG Chem has won the 2nd trial of a patent dispute over the use of DPP-4 inhibitor diabetes drug Zemiglo (gemigliptin). The company was able to reverse its first trial loss and won the second trial, enabling it to prevent patent challengers from launching their generic versions early. The pharmaceutical industry's attention has now turn
- Company
- 'Vyloy' to expand treatment options for gastric cancer
- by Whang, byung-woo Dec 19, 2024 05:52am
- Vyloy (active ingredient: zolbetuximab), a Claudin-18.2-targeting gastric cancer therapy, is rising as the new treatment option for stage 4 gastric cancer despite an issue related to companion diagnostics. As the number of newly diagnosed patients with Claudin-18.2 increases in clinical practices, the drug will be more widely used from the e
